Indications
Pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset Pompe disease (acid ?-glucosidase [GAA] deficiency).
Composition
- Active substance
- Cipaglucosidase alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Pombiliti
- Active substance
- Cipaglucosidase alfa
- ATC code
- A16AB
- Therapeutic area
- Glycogen Storage Disease Type II
- Marketing authorisation holder
- Amicus Therapeutics Europe Limited
- Status